Diisocyanates, as a chemical class, are recognized for their ability t
o cause respiratory and dermal sensitization. By contrast, monofunctio
nal isocyanates have not been associated with cases of clinical sensit
ization. We investigated the immunologic activity of phenyl isocyanate
(PI), an aromatic monoisocyanate, which is a trace constituent in com
mercial diphenyl methane diisocyanate (MDI) products, since it is has
been reported to cause an 'asthma-like' syndrome in rats. The potency
of PI as a contact sensitizer was assessed using the mouse ear swellin
g test. PI was found to be the most potent isocyanate tested yielding
an SD50 (dose predicted to sensitize 50% of the mice) of 0.04 mu mol/k
g, compared with SD50 values of 0.5, 2.1, and 30.4 mu mol/kg, for the
diisocyanate sensitizers hexamethylene diisocyanate, MDI, and toluene
diisocyanate (TDI), respectively. When tested for ability to stimulate
humoral immune responses, antibody titers to PI were more than ten-fo
ld greater than those induced by TDI. The mean hapten-specific IgG ant
ibody titer to PI was 1.4 x 10(4), compared with 1.3 x 10(3) for TDI.
The anti-PI IgG(1) anaphylactic antibody titer (1.2 x 10(4)) was signi
ficantly greater than the anti-TDI IgG(1) titer of 6.4 x 10(2). Hapten
-specific IgE was not detected to either isocyanate. These results ind
icate that phenyl isocyanate is a potent inducer of both cellular and
humoral immune responses. This activity may be a significant contribut
ion to the sensitization potential of commercial products in which it
is a trace contaminant.